» Articles » PMID: 16806467

MRNA Expression of MAGE-A3 Gene in Leukemia Cells

Overview
Journal Leuk Res
Date 2006 Jun 30
PMID 16806467
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Leukemia-associated antigens such as proteins encoded by MAGE genes might provide tools for immunotherapy of leukemia. Positive and negative results of MAGE-A gene expression in hematological malignancies have been reported. This led us to study MAGE-A gene expression in human leukemias using RT-PCR. Among 115 leukemias from various subtypes, 14/34 (41.17%) AML were positive for one of the three genes analyzed (MAGE-A1 1/32; MAGE-A3 10/32; MAGE-B2 3/12). Expression was also detected in 23/76 (30.26%) B-cell ALL patients (MAGE-A1 2/53; MAGE-A3 20/53; MAGE-B2 1/32). One of these patients expressed both MAGE-A1 (weak signal) and -A3 (strong signal) genes. Other patient with CML were positive for MAGE-B2 (1/5, 20%). MAGE-A3 expression data were corroborated by real time RT-PCR through determination of MAGE-A3 transcript levels. We concluded that the MAGE-A3 gene is expressed at the mRNA level in a proportion of human leukemias.

Citing Articles

Overexpression of , , and in Circulating Tumor Cells Derived from Patients with DLBCL Decreases Event-Free Survival.

Ceron R, Martinez A, Ramos C, De la Cruz A, Garcia A, Mendoza I Onco Targets Ther. 2023; 15:1583-1595.

PMID: 36606244 PMC: 9809418. DOI: 10.2147/OTT.S386562.


Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics.

Roussel X, Daguindau E, Berceanu A, Desbrosses Y, Warda W, Neto Da Rocha M Front Oncol. 2020; 10:599933.

PMID: 33363031 PMC: 7757414. DOI: 10.3389/fonc.2020.599933.


T cells targeting multiple tumor-associated antigens as a postremission treatment to prevent or delay relapse in acute myeloid leukemia.

Xue L, Hu Y, Wang J, Liu X, Wang X Cancer Manag Res. 2019; 11:6467-6476.

PMID: 31406473 PMC: 6642655. DOI: 10.2147/CMAR.S205296.


CD8+ TIL recruitment may revert the association of MAGE A3 with aggressive features in thyroid tumors.

Martins M, Marcello M, de Assis Batista F, Cunha L, Morari E, Soares F J Immunol Res. 2015; 2014:921864.

PMID: 25825704 PMC: 4235601. DOI: 10.1155/2014/921864.


Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts.

Srivastava P, Paluch B, Matsuzaki J, James S, Collamat-Lai G, Karbach J Leuk Res. 2014; 38(11):1332-41.

PMID: 25260825 PMC: 5584559. DOI: 10.1016/j.leukres.2014.09.001.